Please assess the completion status of the following clinical trial:

Trial Title: Safety Study of Nicardipine to Treat Cerebral Vasospasm

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female 18 years of age and older~* Subarachnoid hemorrhage documented on head CT~* Fisher Grade 3 or 4~* Hunt Hess Grade 1-5~* Cerebral aneurysm as definitive source of subarachnoid hemorrhage~* Cerebral aneurysm must be treated via open or endovascular techniques~* Presence of external ventricular drain~* Written informed consent obtained from subject or subject's legally authorized representative~Exclusion Criteria:~* Absence or inability to have an external ventricular drain (coagulopathy)~* Non-aneurysmal subarachnoid hemorrhage (perimesencephalic)~* Untreated cerebral aneurysm~* Inability to be randomized prior to post-hemorrhage day 4~* Elevated intra-cranial pressures that would preclude external ventricular drain clamping for 30-60 minutes~* Inability to administer study medication (severe intra-ventricular hemorrhage, occluded external ventricular drain)~* Inability to obtain angiography (coagulopathy, renal failure)~* Pregnant~* Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nicardipine hydrochloride (Type: EXPERIMENTAL): Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
- Preservative-free normal saline (Type: PLACEBO_COMPARATOR): Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.

Based on this trial design, predict the completion outcome and termination type (if applicable).